• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Effects of anti-TNF biologic drugs on uveitis severity in Beh?et patients: systematic review and Meta-analysis

    2022-05-15 05:40:38SomayehAbolhasaniAlirezaKhabbaziForooghHosseiniShivaGholizadehGhalehAzizShahriarAlipour
    關(guān)鍵詞:管理制度馬鈴薯司法

    INTRODUCTION

    Beh?et’s disease (BD) was first discovered by Hulusi Beh?et

    . The geographical distribution of BD is related to the Silk Road rout. The disease is widespread in Middle Eastern,Far Eastern and Mediterranean countries such as Iran, Turkey,Tunisia, China, and Japan

    . The highest incidence of BD is in Turkey (80 to 370 patients per 100 000 population). The prevalence of the disease in Japan is about 13.5 per 100 000 and in Iran 80 per 100 000

    . It is a vasculitis associated with oral and genital ulcers, skin lesions and ocular involvement

    .Ocular involvement is in the form of recurrent non-granulomatous uveitis that can affect the anterior and posterior chambers of the eye. Uveitis is usually bilateral

    . However, the intestine and the central nervous system can also be affected

    .

    Management and treatment of BD is a serious challenge due to different clinical aspects. Therefore, treatment should be proportional to the patient’s condition and severity of clinical symptoms

    . Colchicine and non-steroidal anti-inflammatory drugs are often used to treat joint and mucosal involvement.However, more aggressive methods and immune suppressive agents are needed to treat severe symptoms such as uveitis,retinal vasculitis, neurological and gastrointestinal involvement

    .Current treatment focuses on reducing inflammation and controlling the immune system. For severe manifestation of the disease, high dose corticosteroids are used

    .

    第一,在招投標(biāo)階段,招標(biāo)單位要保證招標(biāo)程序合法公平,盡量選擇信譽(yù)度高、技術(shù)過硬、有實(shí)力且報(bào)價(jià)相對(duì)較低的建設(shè)施工單位,嚴(yán)禁通過不合理方式獲取工程承包權(quán)及濫用私權(quán)行為的出現(xiàn)。第二,在工程建設(shè)過程中,承包商要結(jié)合施工合同的各項(xiàng)條款,采取科學(xué)有效的施工進(jìn)度管理措施,加強(qiáng)對(duì)分包事項(xiàng)等的監(jiān)督管理,同時(shí)監(jiān)理方要充分體現(xiàn)出自身的監(jiān)督職能作用,強(qiáng)化管理與控制,確保工程建設(shè)的順利開展。第三,在竣工驗(yàn)收階段,要根據(jù)合同約定的工程數(shù)量與質(zhì)量,并結(jié)合相關(guān)標(biāo)準(zhǔn)進(jìn)行驗(yàn)收,確保工程質(zhì)量的合格,防止因質(zhì)量不合格出現(xiàn)返工,甚至安全危險(xiǎn)因素等,進(jìn)而影響工程按期交付使用情況的發(fā)生。

    BD patients have high levels of proinflammatory cytokines such as IL-1, IL-2, IL-6, tumor necrosis factor (TNF-α), IL-12,IL-17, IL-18, and IL-23R

    . TNF-α is an inflammatory cytokine that plays a role in homeostasis and immune response and in fact, it plays a major role in autoimmune diseases pathogenesis

    . This cytokine is encoded in the class 3 region of the HLA complex adjacent to HLA-B

    . TNF-α is secreted by many types of cells such as macrophages,monocytes and lymphocytes

    . Anti-TNF drugs are a group of medications that suppresses the physiologic response to

    隨著油田企業(yè)業(yè)務(wù)的開展,檔案資料的內(nèi)容也逐漸增加,給檔案管理工作帶來了更高的難度。此外,對(duì)于油田企業(yè)的檔案來說,不僅僅需要做好保存工作,而且要挖掘檔案的潛在價(jià)值,為當(dāng)前工作更高質(zhì)量、更高效率地開展提供必要的借鑒。而這些工作的開展,都離不開一套完善的檔案信息化管理制度。由于油田企業(yè)對(duì)于檔案管理工作重視不足,配套的信息化管理制度也沒有建立起來。有些企業(yè)即便是有檔案信息化數(shù)據(jù)運(yùn)行管理制度,在實(shí)際工作中沒有嚴(yán)格執(zhí)行,管理制度形同虛設(shè),檔案管理人員工作中存在較大的隨意性。

    TNF-α. The medications in this class include infliximab,etanercept, adalimumab, certolizumab pegol and golimumab.Infliximab, adalimumab, and golimumab are monoclonal antibodies against TNF-α. Etanercept is a soluble, divalent TNF-α receptor that binds to TNF-α to prevent it from binding to its receptor on the cell. Certolizumab pegol is the antigenbinding fragment (Fab’) of a humanized monoclonal antibody that has been conjugated to polyethylene glycol. Induction of antibodies against TNF is largely dependent on its structure,chimeric drugs have a higher capacity to stimulate the immune system than human drugs

    .

    The essential purposes in the management of patients with Beh?et’s uveitis are fast elimination of visual inflammation,avoidance of recurrent attacks, getting of whole remission,and maintenance of vision. Corticosteroids are generally used for the treatment of episodes of inflammation; however, their long-term use is associated with unacceptable side effects.Relapses are normal in the setting of steroid mono-therapy,and conventional immunosuppressive drugs have usually been used for long-term treatment

    .

    The combination of azathioprine and cyclosporine is more impressive than is immunotherapy with either factor, or combination therapy is used as a severe immunosuppressive regimen for the treatment of patients with severe Beh?et’s uveitis

    . In addition, we did not find any studies comparing infliximab with steroids. However, in some studies, infliximab was compared with cyclosporine, and the results showed that following the use of infliximab, the conditions of ocular inflammation were greatly reduced

    .

    Anti-TNF drugs that has been approved for treatment of rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis and has been used for the treatment of uveitis in BD with promising results

    . In general, anti-TNFs such as infliximab have been used to treatment uveitis, and anti-TNFs such as etanercept have been used to treat skin lesions

    . Some studies have suggested that long-term use of biologic drugs can lead to infection in some patients. However, some other studies have shown that no side effects lead to infection of the skin, soft tissues and joints

    . In some other studies, it has been reported to cause cancer in people who have taken these drugs for a long time. But in general, none has been proven

    .However, due to inconsistent results of the present studies and the lack of systematic study, this study is intended to evaluate the therapeutic effects of anti-TNF agents in BD patients with ocular involvement.

    MATERIALS AND METHODS

    After determining the search keywords,including Beh?et’s disease, Beh?et’s syndrome, adamantiades-Beh?et’s disease, anti-TNF agents and uveitis, they were searched both using MeSH keywords and freely in the databases of MEDLINE, Scopus, CINHAL, Psycoinfo,Cochrane Library, Proquest. Iranmedex, SID, IranDoc, Magiran databases were also searched for information in Persian. In addition to the above databases, the list of selected study resources as well as related conferences was searched manually.

    早白堊世華北克拉通東部進(jìn)入破壞峰期,淺部地質(zhì)以伸展活動(dòng)為特征,廣泛出現(xiàn)斷陷盆地,而深部過程以巖石圈轉(zhuǎn)型與減薄為特征,主要表現(xiàn)形式為巖漿活動(dòng)[18]。

    All articles were searched until May 2020 and studies were included in our research that met the inclusion criteria and included: 1) were published by May 2020; 2) studies were designed pre and post anti-TNF drug treatment; 3) were consistent in terms of keywords (in the field of BD, anti-TNF drugs, visual acuity, conflict and ocular attack); 4) contained information of the original article type; 5)had sufficient information such as best-corrected visual acuity(BCVA) or decimal or visual acuity logMAR score.

    Exclusion criteria also included: 1) in terms of keywords in the title and abstract screening stage did not match; 2) review and duplicate studies were excluded; 3) studies unrelated to Beh?et and eye involvement and lacked visual acuity score; 4) nonhuman studies (for example in the mouse).

    After identifying the final articles, the articles were sorted by publication date. Before extracting the data,the tables required for this study were designed based on the required criteria in the extraction table in excel software environment. Then, two authors separately and independently extracted the required data from the final selected articles based on pre-prepared tables.

    馬鈴薯品種、種植地土壤營(yíng)養(yǎng)、栽植方式等均會(huì)對(duì)播種密度產(chǎn)生直接影響,而播種密度又會(huì)直接影響馬鈴薯的產(chǎn)量及品質(zhì)。通常情況下早熟型馬鈴薯品種播種密度要稍大于晚熟型品種,育種馬鈴薯密度要高于商品馬鈴薯;制作淀粉的種植密度要大于制作薯?xiàng)l的種植密度。

    According to the contents mentioned in this section, in the first stage after the initial search, the number of articles included in the study was 1504, of which 523 were duplicate articles(981 articles remaining). Finally, according to the mentioned criteria, only 15 articles were found to be completely relevant,of which 12 articles were included in the analysis related to the visual acuity criterion (Figure 1).

    The visual prognosis in BD is affected by severe recurrence of uveitis. Recurrent attacks of ocular inflammation lead to structural changes that may lead to visual impairment and even blindness in patients if not treated promptly and appropriately. The main goal of Beh?et’s uveitis management is to quickly eliminate inflammation inside the eye, prevent recurrent attacks and maintain vision in these patients. TNF-α is a factor that plays a pivotal role in the development and maintenance of the inflammatory response, even though the specific etiopathogenesis of BD has not yet been elucidated but many experimental studies have shown that TNF-α plays an important role in the progression and persistence of ocular inflammation in BD

    . Therefore, in order to better understand which anti-TNF drugs have an effective therapeutic role in BD, we conducted this systematic review and Metaanalysis of data and pooled results.

    After fully extracting the data related to our articles, it was found that only the visual acuity index has been reported in most articles and is common to them and we lastly selected this index for the Meta-analysis. Finally, in case of discrepancies between the data, it was discussed until the same result was reached.

    We assessed the quality of the involved studies using the Cochrane Collaboration’s tool for assessing the risk of bias

    . In this reading, selected studies were judged based on the following criteria: bias related to patient selection (“selection bias”) which is determined based on the complete description of patient selection and their inclusion and exclusion criteria. If patients are carefully selected, they will be considered low risk in terms of bias risk. Measurement bias, which in this study is related to methods of measuring ocular involvement and ocular inflammation and score related to visual acuity. If precise methods are used, the risk is considered low. Follow-up bias, which refers to the length of the follow-up period. If it is mentioned in full detail, the risk is low in terms of bias. Exposure bias was considered as changes in ocular inflammation in patients. If the values related to visual acuity, eye inflammation and eye attacks are reported with great accuracy, it is reported as low risk. Finally,confounding bias is related to the data analysis and results.If the confounding factors such as gender, age, and drug use are carefully observed during the analysis of visual acuity and other factors related to eye inflammation, that study is considered low risk in confounding bias.

    We measured risk of bias using the Cochrane Collaboration’s tool for measuring the risk of bias in randomized trials. We classified bias according to five domains: sample selection bias, measurement bias, follow-up bias, exposure (ocular response) bias, and confounding (correlation) bias. We defined risk of bias as low, high, unclear risk. In most of the studies we reviewed, the inclusion and exclusion criteria were clearly mentioned, and most of them were in the low group. Most studies on the method section and method of assessment the severity of ocular inflammation and visual acuity score were fully explained. Therefore, these options were placed in the low-risk bias group.

    RESULTS

    Findings from Systematic Review

    After systematic review of articles,according to inclusion and exclusion criteria, finally 15 related articles were found, of which 12 articles were included in the Meta-analysis. One study was conducted in the Africa, six studies in European countries, and eight study in Asia. Of the 15 articles found, 9 articles examined the effect of infliximab and 4 articles about adalimumab and two others as a combination of two drugs. In these studies, the dose of infliximab was 5 mg/kg and adalimumab was 40 mg/subcutaneous/2wk. The mean age of the samples was 31.0y and the mean duration of illness and follow-up were 7.88y and 16.72wk, respectively. In these studies, the average duration of use of biological drugs was 18.21mo. The mean dose of prednisolone before and after biological treatments was reported in 5 studies and was 28.56 and 7.56 mg/kg, respectively.

    The electronic search, conducted until May 2020, resulted in 1458 abstracts, of which 378 abstracts were reviewed. Of those, 118 full texts were read and 15 found to be eligible (of these, 15 articles were selected for systematic review and among them 12 articles had the necessary properties for Meta-analysis). The reference lists of all 12 case-control were searched for relevant articles. Full texts of the major reviews found were read and their reference lists searched. The study characteristics of the patients enrolled in these studies are summarized in Table 1

    .

    Data for this study were extracted using a pre-designed table. Then, using comprehensive Metaanalyzed CMA.2 software, the data were analyzed by random effect method and the heterogeneity of the studies and their distribution was evaluated and Forrest plot and Funnel plot diagrams were presented.

    The studies also showed that the follow-up range and length of patients is either fully explained or incomplete. Because of this, they were either low or high risk in terms of followup bias. The bias of ocular response (exposure bias) was fully focused in most studies. Therefore, the bias of this option was considered low risk. Finally, in most studies, confounding factors such as gender, age, and medication use were carefullyconsidered during the analysis of visual acuity and other factors associated with ocular inflammation. For this reason,in most of them, low-risk bias was considered. The risk of bias in each included study is summarized in Table 2 and Figure 2.

    The articles and documents obtained from the search were screened in several stages in terms of title, abstract and full text, and the final studies with inclusion criteria were selected.The studies were evaluated by 2 experts and using a checklist(PRISMA) in terms of the types of bias risks (selection,performance, report, attrition,

    .) as well as content, critique and low-quality studies were discarded. Also, in case of disagreement between the experts, the third person was used and a group discussion was held. Relevant data were then extracted from the studies using a designed table.

    Data was entered in Comprehensive Meta-Analysis (CMA) 2.2 (BioStat Inc., US)and random-effect models were used. Assessment of risk of bias in included studies has been considered. The visual acuity logMAR score as the primary outcome variable was expressed as continuous variables. Standard deviation was calculated using actual

    -values obtained from

    -tests quoted by Cochrane. For every study, we calculated the mean difference(MD) for the primary outcome visual acuity logMAR score using 95% confidence interval (95%CI). The outcome measures were pooled by use of the random-effect model.Heterogeneity was calculated using Cochrane’s

    statistic and quantified using the

    statistic. These indicated the proportion of variability across studies due to heterogeneity, rather than sample error. In the case of missing data, efforts to contact authors were made.

    把握了上述三類“道”義,我們不難看出作者的思想,這有助于對(duì)“道”的英譯。然而,文中“道”的含義廣博,尤其是儒道之“道”,很難在英語世界找到相應(yīng)的對(duì)應(yīng)詞,獲得傳神達(dá)意的得體譯本。筆者姑且選取劉師舜、楊憲益、戴乃迭夫婦以及羅經(jīng)國(guó)這三個(gè)經(jīng)典譯本(以下分別簡(jiǎn)稱劉譯、楊譯、羅譯),將對(duì)應(yīng)的“道”的譯文摘出,按上文“道”的釋義及分類順序分別列舉如下(粗體為筆者所加):

    Asymmetry assessment of the funnel plot was con ducted for publication bias only to showcase the sample interventions.There was a slight asymmetry in Begg’s funnel plot, we did not find any evidence of publication bias for visual acuity logMAR (Egger’s test

    =2.54,

    =0.05, Begg’s test

    =0.6,

    =0.54; Figure 4).

    The preliminary results indicate a nonsignificant reduction in visual acuity logMAR score (MD=-1.5 IU/L, 95%CI:-2.1, -0.01). However, significant heterogeneity was revealed among studies (

    =154.97,

    =92.9%,

    <0.001). Despite a high

    , results were pooled, as examination of these studies on a Forest plot indicated that the individual trial results were consistent in the direction of the effect (

    , MD and confidence intervals largely fell on one side of the null line;Figure 3). Characteristics of age, sex ratios, and baseline visual acuity were similar across all trials. Table 1 highlights the characteristics of the included studies.

    DISCUSSION

    These data include general data of articles (name of the first authors of the articles, name of the country of study, year of study, sample size, age of individuals, length of treatment,and length of follow-up), data related to interventions (type of drug used, drug dose, names of other drugs (steroid and nonsteroidal drugs), response data (BCVA score, ocular attacks,prednisolone dose pre and post anti-TNF drug used).

    由于本工程地下水位位于樁底以上,全干孔作業(yè)需要先行降低地下水位,實(shí)施難度大,成本花費(fèi)高,安全系數(shù)低,故不予考慮;濕孔作業(yè)能達(dá)到施工要求,但近年來,鄭州市環(huán)保要求高,鉆孔泥漿造成大量污染,儲(chǔ)存及運(yùn)輸難度大,不利于環(huán)境治理。故綜合考慮選擇半濕孔鉆孔作業(yè),既加快了進(jìn)度,減少了投入,又有利于環(huán)境治理。

    The TNF-α is a pro-inflammatory cytokine which can adjust immune cells’ activity in autoimmune diseases. Since BD is a kind of autoimmune disease, therefore, TNF-α plays a significant role in causing inflammation in BD

    . Research shows that high levels of TNF-α and its receptors are present in the serum or plasma of BD patients along with other proinflammatory cytokines

    . Accordingly, blocking the TNF-α pathway can be considered as the first or second-line valid treatment in BD patients with ocular symptoms and uveitis. Anti-TNF drugs as a new therapeutic approach are the strategic alternative to traditional safety immunosuppressant

    while the results of infliximab have been very encouraging for the treatment of severe uveitis in BD

    .

    (3)洗胃后心里護(hù)理。首先,為患者創(chuàng)造一個(gè)良好的病房環(huán)境,保護(hù)其隱私。同時(shí),安排家屬在身邊陪伴;其次,與患者采取一對(duì)一溝通模式,引導(dǎo)患者將內(nèi)心情緒全面化表達(dá)出來,做深入化心理疏導(dǎo)。幫助患者正確認(rèn)知自己,以采用積極的心態(tài)面對(duì)問題,提高其心理承受力、社會(huì)適應(yīng)力;

    The researchers showed that anti-TNF-α regulates peripheral blood CD4+ T cells in patients with posterior intraocular inflammation, which is associated with improved visual function. In one study, researchers have been found that infliximab injections in patients with BD reduced the number of TNF-secreting peripheral blood mononuclear cells

    , which in turn reduced eye attacks and improved vision in patients

    .

    This study confirmed the efficacy of anti-TNF therapy (infliximab or adalimumab) for treating refractory uveitis associated with BD. Also, the results related to the number of ocular inflammatory attacks in these patients have been shown that the number of attacks after the addition of biological anti-TNF therapies has decreased significantly as shown in earlier studies. Since the use of some drugs can interfere with the results of the study, so these studies were not included in the results and were excluded from our study. However, in most studies, patients have used the same drugs to treat the disease, and in the end, only the results of prednisolone,which had a decreasing trend, have been reported in some studies

    . The results of some previous studies on the effects of these drugs may seem contradictory. One of the main reasons for the contrary results of the studies may be due to the fact that the patients studied in this research used different immunosuppressive drugs, some patients have used corticosteroids, and others have used drugs such as colchicine,azathioprine, and cyclosporine. Also, the dose and duration of drugs use have varied in different people, and all of these can affect the final results of these studies. In general, most treatments are used to reduce the dose of steroid drugs, which these drugs (anti-TNF) have also been associated with a significant reduction in the use of steroid drugs.

    為貫徹落實(shí)《國(guó)家信息化發(fā)展戰(zhàn)略綱要》《“十三五”國(guó)家信息化規(guī)劃》《全國(guó)司法行政“十三五”發(fā)展規(guī)劃》,全面推進(jìn)司法行政信息化建設(shè)發(fā)展,司法部于2017年7月12日發(fā)布的《關(guān)于印發(fā)〈“十三五”全國(guó)司法行政信息化發(fā)展規(guī)劃〉的通知》(司發(fā)通[2017]75號(hào)),明確提出司法鑒定管理信息化的管理要求。因此司法鑒定機(jī)構(gòu)信息化建設(shè)是響應(yīng)國(guó)家司法行政信息化發(fā)展的要求。對(duì)于緊跟司法行政管理政策,提高機(jī)構(gòu)鑒定質(zhì)量和效率,增強(qiáng)鑒定機(jī)構(gòu)管理和服務(wù)能力,促進(jìn)信息公開和社會(huì)監(jiān)督,具有十分重要的意義。

    One of the main limitations of this study may be the relatively low sample size in the studies. Other limiting factors include confounding factors such as patients’ age, medications used,type of medication, and dose of medication before biological drugs are added. However, in some studies, these factors were considered as confounders and the final results were reported.In conclusion, however, the overall results of this study show that the use of biologic drugs (anti-TNF drugs) along with other therapeutic drugs, has been effective on patients’ visual acuity and has led to a significant improvement in them.Also, the amount of eye attacks in them has been significantly reduced. In addition, since the long-term use of corticosteroid drugs can be harmful, simultaneous use of biological drugs can reduce the dose of prednisolone.

    長(zhǎng)石礦物量較少(<5%),但礦物種類繁多,主要為鉀長(zhǎng)石,偶見有條紋長(zhǎng)石、微斜長(zhǎng)石和鈉長(zhǎng)石等。現(xiàn)主要對(duì)鉀長(zhǎng)石的嵌布特征描述如下:

    None;

    None;

    None;

    None;

    None.

    1 Bulur I, Onder M. Beh?et disease: new aspects.

    2017;35(5):421-434.

    2 Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH.Epidemiology of Beh?et disease.

    2012;20(5):324-335.

    3 Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E,Inanc M, Gül A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine,cyclosporine, and corticosteroids in Beh?et’s disease: an open-label trial.

    2005;52(8):2478-2484.

    4 Fabiani C, Sota J, Vitale A,

    . Cumulative retention rate of adalimumab in patients with Beh?et’s disease-related uveitis: a fouryear follow-up study.

    2018;102(5):637-641.

    5 Lopalco G, Emmi G, Gentileschi S,

    . Certolizumab Pegol treatment in Beh?et’s disease with different organ involvement: a multicenter retrospective observational study.

    2017;27(6):1031-1035.

    6 Vallet H, Riviere S, Sanna A,

    Efficacy of anti-TNF alpha in severe and/or refractory Beh?et’s disease: multicenter study of 124 patients.

    2015;62:67-74.

    7 Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H. A double-blind trial of depot corticosteroids in Beh?et’s syndrome.

    (

    ) 2005;45(3):348-352.

    8 Mendes D, Correia M, Barbedo M,

    . Beh?et’s disease - a contemporary review.

    2009;32(3-4):178-188.

    9 Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Beh?et’s disease.

    2012;11(10):699-704.

    10 Dilek K, Oz?imen AA, Saricao?lu H, Saba D, Yücel A, Yurtkuran M,Yurtkuran M, Oral HB. Cytokine gene polymorphisms in Beh?et’s disease and their association with clinical and laboratory findings.

    2009;27(2 Suppl 53):S73-S78.

    11 Alipour S, Nouri M, Khabbazi A, Samadi N, Babaloo Z, Abolhasani S,Farhadi J, Roshanravan N, Jadideslam G, Sakhinia E. Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Beh?et’s disease.

    2018;119(8):6614-6622.

    12 Abolhasani S, Gholizadeh Ghaleh Aziz S, Khabbazi A, Alipour S.Determination of the relationship between the severity of Beh?et’s disease and the expression and methylation of IL-10, IL-6 and IL-8 genes.

    2018;4(1):6-14.

    13 Alipour S, Sakhinia E, Khabbazi A,

    . Methylation status of interleukin-6 gene promoter in patients with Beh?et’s disease.

    (

    ) 2020;16(3):229-234.

    14 Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ríos-Fernández R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Beh?et’s disease, sarcoidosis, and noninfectious uveitis.

    2013;2013:286857.

    15 Aziz SGG, Aziz SGG, Khabbazi A, Alipour S. The methylation status of

    -α and

    promoters and the regulation of these gene expressions in patients with Beh?et’s disease.

    2020;25(5):384-390.

    16 Ate? A, Kinikli G, Düzgün N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Beh?et’s disease.

    2006;26(4):348-353.

    17 Emi Aikawa N, Carvalho JF, Artur Almeida Silva C, Bonfá E.Immunogenicity of anti-TNF-α agents in autoimmune diseases.

    2010;38(2-3):82-89.

    18 Kaklamani VG, Kaklamanis PG, editors.

    Elsevier; 2001.

    19 Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z,Hasanreisoglu B. Interferon alpha-2a therapy in patients with refractory beh?et uveitis.

    2017;25(1):71-75.

    20 Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M.Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh?et disease.

    2010;94(3):284-288.

    21 Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS.Infliximab therapy for the treatment of refractory ocular inflammatory disease.

    2007;125(7):895-900.

    22 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-tnf therapy in Crohn’s disease.

    2018;19(8):2244.

    23 Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P,Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh?et’s disease.

    2001;358(9278):295-296.

    24 Atzeni F, Gianturco L, Talotta R, Varisco V, Ditto MC, Turiel M,Sarzi-Puttini P. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?

    2015;7(4):353-361.

    25 Ding TN, Deighton C. Complications of anti-TNF therapies.

    2007;2(6):587-597.

    26 Higgins JP, Thomas J, Chandler J,

    .

    . John Wiley & Sons; 2019.

    27 Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C,Cimino L, Gini G, Lenzetti I, Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Beh?et’s disease: a 24-month followup study.

    (

    ) 2007;46(7):1161-1164.

    28 Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G.One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh?et’s disease refractory to standard immunosuppressive drugs.

    2011;31(1):33-37.

    29 Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H,Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

    2012;56(6):536-543.

    30 Fabiani C, Vitale A, Emmi G,

    . Efficacy and safety of adalimumab in Beh?et’s disease-related uveitis: a multicenter retrospective observational study.

    2017;36(1):183-189.

    31 Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Longterm clinical outcomes in patients with refractory uveitis associated with Beh?et disease treated with infliximab.

    2013;21(6):468-474.

    32 Ho M, Chen LJ, Sin HPY, Iu LPL, Brelen M, Ho ACH, Lai TYY,Young AL. Experience of using adalimumab in treating sightthreatening paediatric or adolescent Beh?et’s disease-related uveitis.

    2019;9(1):14.

    33 Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R,Neumann R, Kramer M. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.

    2018;256(4):801-808.

    34 El Garf AK, Shahin AA, Shawky SA, Azim MA, Effat DA,Abdelrahman SK. Efficacy of infliximab in refractory posterior uveitis in Beh?et's disease patients.

    2018;40(2):93-97.

    35 Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Beh?et’s uveitis: a retrospective long-term followup study.

    2014;32(4 Suppl 84):S58-S62.

    36 Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka H. Health- and vision-related quality of life in patients receiving infliximab therapy for Beh?et uveitis.

    2013;97(3):338-342.

    37 Ueda S, Akahoshi M, Takeda A,

    . Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Beh?et’s disease.

    2018;5(1):9-15.

    38 Bawazeer A, Raffa LH, Nizamuddin SHM. Clinical experience with adalimumab in the treatment of ocular Beh?et disease.

    2010;18(3):226-232.

    39 Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh?et’s disease on infliximab therapy.

    2011;95(9):1245-1250.

    40 Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V,

    . Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh?et’s disease: national multicenter study of 177 cases.

    2019;71(12):2081-2089.

    41 Hu YW, Huang ZH, Yang SZ, Chen XQ, Su WR, Liang D.Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Beh?ets’ disease-associated uveitis: a systematic review and meta-analysis.

    2020;11:941.

    42 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis.

    2015;60(6):575-589.

    43 Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S,Hamuryudan V, Yazici H. Short-term trial of etanercept in Beh?et's disease: a double blind, placebo controlled study.

    2005;32(1):98-105.

    44 Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

    2007;56(10):3248-3252.

    45 Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y,Ohno S, Ishida S. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Beh?et’s disease with infliximab.

    2012;250(7):1081-1087.

    46 Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R. Effects of infliximab in the treatment of refractory posterior uveitis of Beh?et’s disease after withdrawal of infusions.

    2010;30(5):577-581.

    47 Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y. Cytokine production profile in patients with Beh?et’s disease treated with infliximab.

    2003;24(5):210-218.

    猜你喜歡
    管理制度馬鈴薯司法
    馬鈴薯有功勞
    探討企業(yè)內(nèi)控管理制度的建立與完善
    制定法解釋中的司法自由裁量權(quán)
    法律方法(2021年4期)2021-03-16 05:34:28
    司法所悉心調(diào)解 墊付款有了著落
    非正式司法的悖謬
    食品安全公共管理制度的缺失與完善評(píng)析
    涉軍中小企業(yè)管理制度創(chuàng)新探討
    定邊馬鈴薯
    胖胖的馬鈴薯
    論司法公開的困惑與消解
    精品久久久精品久久久| 亚洲熟妇熟女久久| 亚洲七黄色美女视频| 非洲黑人性xxxx精品又粗又长| 亚洲第一电影网av| 老司机在亚洲福利影院| 一a级毛片在线观看| 成在线人永久免费视频| 国内精品久久久久久久电影| 黄色毛片三级朝国网站| 一进一出抽搐gif免费好疼| 久久精品国产清高在天天线| 亚洲欧美一区二区三区黑人| 亚洲欧美精品综合久久99| 亚洲av成人一区二区三| 纯流量卡能插随身wifi吗| 国产亚洲精品第一综合不卡| 亚洲 国产 在线| 国产精品久久视频播放| 91国产中文字幕| 男人操女人黄网站| 成人亚洲精品av一区二区| 国产在线精品亚洲第一网站| 久久人人爽av亚洲精品天堂| 男男h啪啪无遮挡| 9热在线视频观看99| 国产一级毛片七仙女欲春2 | 丝袜美足系列| 免费一级毛片在线播放高清视频 | 国产av精品麻豆| 国产精品久久久久久人妻精品电影| 一本久久中文字幕| 别揉我奶头~嗯~啊~动态视频| 国产一区二区三区在线臀色熟女| 亚洲性夜色夜夜综合| 欧美在线一区亚洲| 欧美色视频一区免费| 91麻豆av在线| 丝袜美足系列| 天天躁夜夜躁狠狠躁躁| 久久中文看片网| 成在线人永久免费视频| 深夜精品福利| 亚洲精品美女久久久久99蜜臀| 99国产精品免费福利视频| 99国产综合亚洲精品| 色播亚洲综合网| 给我免费播放毛片高清在线观看| 美女 人体艺术 gogo| 校园春色视频在线观看| 久久热在线av| 好看av亚洲va欧美ⅴa在| 国产视频一区二区在线看| 999久久久国产精品视频| 麻豆久久精品国产亚洲av| 亚洲欧美日韩无卡精品| 国产精品久久久久久人妻精品电影| 精品久久久久久成人av| 在线观看66精品国产| 久久精品aⅴ一区二区三区四区| 啪啪无遮挡十八禁网站| 成人18禁高潮啪啪吃奶动态图| 少妇 在线观看| 久热这里只有精品99| 亚洲黑人精品在线| 国产日韩一区二区三区精品不卡| 国产99白浆流出| 国产精品二区激情视频| 在线观看日韩欧美| 亚洲国产日韩欧美精品在线观看 | 天堂√8在线中文| 后天国语完整版免费观看| 国产成人av激情在线播放| 亚洲精品在线美女| 国产一区二区激情短视频| 欧美日韩福利视频一区二区| 一区二区三区国产精品乱码| 一进一出抽搐gif免费好疼| 亚洲av日韩精品久久久久久密| 日本一区二区免费在线视频| 国产成+人综合+亚洲专区| 亚洲成人精品中文字幕电影| 精品国产乱码久久久久久男人| 极品人妻少妇av视频| 色播在线永久视频| 美女免费视频网站| 一个人观看的视频www高清免费观看 | 黑丝袜美女国产一区| 国产精品精品国产色婷婷| 亚洲精品久久国产高清桃花| 国产欧美日韩一区二区精品| 国产精品亚洲av一区麻豆| 免费观看精品视频网站| 黄色成人免费大全| 人人妻,人人澡人人爽秒播| 精品人妻1区二区| 国产一区二区在线av高清观看| 啪啪无遮挡十八禁网站| 亚洲一区高清亚洲精品| 一级毛片精品| 精品少妇一区二区三区视频日本电影| 日韩成人在线观看一区二区三区| 99热只有精品国产| 日日干狠狠操夜夜爽| 香蕉国产在线看| 成人国语在线视频| 国产片内射在线| 一级毛片精品| 国产亚洲精品久久久久久毛片| 韩国精品一区二区三区| 亚洲国产看品久久| 亚洲精品粉嫩美女一区| 99国产精品一区二区蜜桃av| 久99久视频精品免费| 久久久久精品国产欧美久久久| 国产激情欧美一区二区| 岛国在线观看网站| www.自偷自拍.com| 91成人精品电影| 亚洲成人国产一区在线观看| 香蕉丝袜av| 好男人在线观看高清免费视频 | 国产单亲对白刺激| 久久青草综合色| 国产精品99久久99久久久不卡| 欧美日本亚洲视频在线播放| 88av欧美| 亚洲黑人精品在线| 国产成人欧美在线观看| 一级毛片精品| 国产99白浆流出| 中文字幕人成人乱码亚洲影| av有码第一页| 嫩草影院精品99| 欧美成人一区二区免费高清观看 | 人妻久久中文字幕网| 熟女少妇亚洲综合色aaa.| 中文字幕久久专区| 不卡av一区二区三区| 999久久久精品免费观看国产| 波多野结衣av一区二区av| 亚洲一区二区三区色噜噜| 欧美亚洲日本最大视频资源| 搡老岳熟女国产| 国产成年人精品一区二区| av视频在线观看入口| a级毛片在线看网站| 性少妇av在线| 国产精品一区二区在线不卡| 丝袜美足系列| 久久婷婷成人综合色麻豆| 亚洲国产精品999在线| 日韩三级视频一区二区三区| 欧美黑人欧美精品刺激| 丰满的人妻完整版| 大陆偷拍与自拍| 51午夜福利影视在线观看| 高清毛片免费观看视频网站| 亚洲第一欧美日韩一区二区三区| 亚洲精品av麻豆狂野| 一边摸一边做爽爽视频免费| 在线观看一区二区三区| 91av网站免费观看| 国产麻豆成人av免费视频| 中文字幕久久专区| 成人特级黄色片久久久久久久| 99re在线观看精品视频| 日本免费a在线| x7x7x7水蜜桃| 窝窝影院91人妻| 麻豆久久精品国产亚洲av| 亚洲,欧美精品.| 亚洲七黄色美女视频| 久久久国产成人精品二区| 正在播放国产对白刺激| 国产亚洲欧美精品永久| 国产成人啪精品午夜网站| 日韩大尺度精品在线看网址 | 男人舔女人下体高潮全视频| 波多野结衣av一区二区av| 久久天堂一区二区三区四区| 色综合站精品国产| 久久人妻福利社区极品人妻图片| a在线观看视频网站| 成年女人毛片免费观看观看9| 侵犯人妻中文字幕一二三四区| 99在线人妻在线中文字幕| 久久草成人影院| 国产99白浆流出| 香蕉丝袜av| 国产日韩一区二区三区精品不卡| 国产又爽黄色视频| tocl精华| 亚洲色图综合在线观看| 亚洲av五月六月丁香网| 午夜日韩欧美国产| 精品国产超薄肉色丝袜足j| 国产私拍福利视频在线观看| 午夜精品在线福利| 久久国产亚洲av麻豆专区| 亚洲av成人不卡在线观看播放网| 国产av精品麻豆| 精品久久蜜臀av无| 国产精品1区2区在线观看.| 国产精品久久久人人做人人爽| 麻豆av在线久日| 久久人人爽av亚洲精品天堂| 亚洲精品中文字幕在线视频| 99国产精品免费福利视频| 中文字幕人妻熟女乱码| 久久午夜综合久久蜜桃| 亚洲最大成人中文| 男人舔女人下体高潮全视频| 狠狠狠狠99中文字幕| 日韩欧美在线二视频| 精品久久久精品久久久| 欧美日本亚洲视频在线播放| 黑丝袜美女国产一区| 精品无人区乱码1区二区| 看黄色毛片网站| 好男人电影高清在线观看| 成人免费观看视频高清| 人人妻人人澡人人看| 色综合婷婷激情| 久久国产乱子伦精品免费另类| 日日干狠狠操夜夜爽| 国产激情久久老熟女| 国产精品99久久99久久久不卡| 国产免费av片在线观看野外av| 三级毛片av免费| 国语自产精品视频在线第100页| 国产精品九九99| 精品久久久久久成人av| 最好的美女福利视频网| 女警被强在线播放| 日本黄色视频三级网站网址| 人成视频在线观看免费观看| 日日摸夜夜添夜夜添小说| 国产不卡一卡二| 免费在线观看黄色视频的| 成年版毛片免费区| 久久人妻熟女aⅴ| 欧美一级a爱片免费观看看 | 黑人巨大精品欧美一区二区mp4| 大陆偷拍与自拍| 黄色a级毛片大全视频| 亚洲国产精品sss在线观看| 成年人黄色毛片网站| 欧美绝顶高潮抽搐喷水| 精品久久久久久久毛片微露脸| 亚洲欧洲精品一区二区精品久久久| 国产精品影院久久| 如日韩欧美国产精品一区二区三区| 女性被躁到高潮视频| 国产黄a三级三级三级人| 亚洲男人的天堂狠狠| 成人国产一区最新在线观看| 成人手机av| 天天一区二区日本电影三级 | 国产精品国产高清国产av| 欧美激情极品国产一区二区三区| 天堂影院成人在线观看| 国产又色又爽无遮挡免费看| 国产97色在线日韩免费| 亚洲av成人不卡在线观看播放网| 狠狠狠狠99中文字幕| 国产精品 欧美亚洲| 国产野战对白在线观看| 中亚洲国语对白在线视频| 久久午夜综合久久蜜桃| 久久婷婷人人爽人人干人人爱 | 国产91精品成人一区二区三区| 夜夜夜夜夜久久久久| 999久久久精品免费观看国产| 国产精品久久久久久人妻精品电影| 午夜影院日韩av| 一区二区三区精品91| 两性午夜刺激爽爽歪歪视频在线观看 | 少妇 在线观看| 国产伦人伦偷精品视频| 窝窝影院91人妻| 欧美av亚洲av综合av国产av| 琪琪午夜伦伦电影理论片6080| 亚洲国产看品久久| 国产精品久久久久久人妻精品电影| 人妻久久中文字幕网| 又黄又爽又免费观看的视频| 亚洲国产精品999在线| 精品免费久久久久久久清纯| 日韩欧美在线二视频| 国产亚洲av高清不卡| 亚洲精品粉嫩美女一区| 夜夜夜夜夜久久久久| 欧美日韩精品网址| 国产成年人精品一区二区| x7x7x7水蜜桃| 亚洲色图av天堂| 中文字幕人妻丝袜一区二区| 女警被强在线播放| 日韩国内少妇激情av| 欧美老熟妇乱子伦牲交| 99香蕉大伊视频| 欧美乱码精品一区二区三区| 久久亚洲精品不卡| 一区在线观看完整版| 亚洲av片天天在线观看| 午夜福利欧美成人| 女人被狂操c到高潮| 日韩欧美国产一区二区入口| 国产欧美日韩综合在线一区二区| 日本免费一区二区三区高清不卡 | 亚洲欧美激情在线| 久久天躁狠狠躁夜夜2o2o| 日韩国内少妇激情av| 国产精品精品国产色婷婷| 久久国产亚洲av麻豆专区| 亚洲av成人av| 一级毛片女人18水好多| 欧美日本中文国产一区发布| 国产成人av激情在线播放| 国产一卡二卡三卡精品| 黄色丝袜av网址大全| 美女午夜性视频免费| 国内精品久久久久久久电影| 久久人人97超碰香蕉20202| 国产色视频综合| 中文亚洲av片在线观看爽| 人成视频在线观看免费观看| 欧美精品亚洲一区二区| 电影成人av| 久久久久国产精品人妻aⅴ院| 制服丝袜大香蕉在线| 色播在线永久视频| 嫩草影院精品99| 亚洲中文日韩欧美视频| 大陆偷拍与自拍| 丝袜美足系列| 久久中文字幕人妻熟女| 亚洲av成人一区二区三| 丝袜美腿诱惑在线| 国产亚洲精品一区二区www| 亚洲人成77777在线视频| 脱女人内裤的视频| 亚洲av日韩精品久久久久久密| 窝窝影院91人妻| 国产一卡二卡三卡精品| 亚洲成国产人片在线观看| 午夜两性在线视频| 91av网站免费观看| 午夜福利成人在线免费观看| 久久天躁狠狠躁夜夜2o2o| 在线国产一区二区在线| 亚洲视频免费观看视频| 亚洲色图 男人天堂 中文字幕| 精品久久久精品久久久| 一二三四社区在线视频社区8| 熟女少妇亚洲综合色aaa.| 自线自在国产av| 久久天躁狠狠躁夜夜2o2o| 丝袜美足系列| av在线播放免费不卡| 亚洲人成电影免费在线| 天天一区二区日本电影三级 | 国产成人av教育| 激情在线观看视频在线高清| 国产成人精品无人区| 9191精品国产免费久久| 国内毛片毛片毛片毛片毛片| 色婷婷久久久亚洲欧美| 欧美在线一区亚洲| 亚洲五月色婷婷综合| 久久天躁狠狠躁夜夜2o2o| 少妇 在线观看| 一边摸一边抽搐一进一小说| 在线观看66精品国产| 在线观看午夜福利视频| 亚洲欧美激情在线| 欧美人与性动交α欧美精品济南到| 在线观看www视频免费| 久久久久九九精品影院| 亚洲国产欧美日韩在线播放| 无人区码免费观看不卡| 国产av在哪里看| 欧美丝袜亚洲另类 | 在线播放国产精品三级| 国产精品,欧美在线| 午夜久久久久精精品| 日韩欧美三级三区| 亚洲 欧美一区二区三区| 国产一区二区激情短视频| 一级毛片精品| 俄罗斯特黄特色一大片| 又黄又爽又免费观看的视频| 丝袜人妻中文字幕| 久久久久久免费高清国产稀缺| 久久性视频一级片| 国产高清视频在线播放一区| 性少妇av在线| 一a级毛片在线观看| 日本在线视频免费播放| 日韩欧美三级三区| 国产成人免费无遮挡视频| or卡值多少钱| 国产免费男女视频| 亚洲精华国产精华精| 亚洲人成网站在线播放欧美日韩| 成年人黄色毛片网站| 国产精品综合久久久久久久免费 | 国产一级毛片七仙女欲春2 | av电影中文网址| 亚洲精品中文字幕一二三四区| 亚洲av五月六月丁香网| 国产色视频综合| 国产精品综合久久久久久久免费 | 久久婷婷成人综合色麻豆| 可以在线观看的亚洲视频| 亚洲伊人色综图| 中文字幕色久视频| 色综合亚洲欧美另类图片| 中文字幕最新亚洲高清| 长腿黑丝高跟| 国产亚洲精品综合一区在线观看 | 免费高清在线观看日韩| 黑人操中国人逼视频| 性色av乱码一区二区三区2| 手机成人av网站| 麻豆av在线久日| 亚洲中文字幕一区二区三区有码在线看 | 国产亚洲精品一区二区www| 香蕉丝袜av| 亚洲av五月六月丁香网| 久久午夜亚洲精品久久| 韩国精品一区二区三区| 成人三级做爰电影| 欧美黄色片欧美黄色片| 看黄色毛片网站| 久久人妻熟女aⅴ| 国产精品1区2区在线观看.| 在线观看免费日韩欧美大片| 午夜福利高清视频| 老司机午夜福利在线观看视频| 久久精品aⅴ一区二区三区四区| 精品国产亚洲在线| 久久久精品国产亚洲av高清涩受| 在线视频色国产色| svipshipincom国产片| 日本精品一区二区三区蜜桃| 波多野结衣巨乳人妻| 一夜夜www| 亚洲欧美日韩另类电影网站| 欧美日韩一级在线毛片| av中文乱码字幕在线| 校园春色视频在线观看| 国产精品二区激情视频| 男人的好看免费观看在线视频 | 好看av亚洲va欧美ⅴa在| av视频免费观看在线观看| 日本vs欧美在线观看视频| 国产成人欧美| 国产精品 国内视频| 亚洲午夜理论影院| 欧美午夜高清在线| 国产av又大| 亚洲专区字幕在线| 亚洲av成人av| 亚洲天堂国产精品一区在线| 一级a爱片免费观看的视频| 久久久久九九精品影院| 搞女人的毛片| 欧美日韩亚洲综合一区二区三区_| 中文字幕高清在线视频| 男女床上黄色一级片免费看| 国产精品一区二区免费欧美| 国产一卡二卡三卡精品| 久久久国产成人免费| 国产单亲对白刺激| 自线自在国产av| 很黄的视频免费| www.自偷自拍.com| 热99re8久久精品国产| 色哟哟哟哟哟哟| 香蕉国产在线看| 欧美一区二区精品小视频在线| 亚洲人成电影免费在线| 久久欧美精品欧美久久欧美| 亚洲成a人片在线一区二区| 久久国产乱子伦精品免费另类| 色综合欧美亚洲国产小说| 国产xxxxx性猛交| 久久精品国产99精品国产亚洲性色 | 丝袜美足系列| 久久亚洲真实| 国产高清视频在线播放一区| 中出人妻视频一区二区| 91精品三级在线观看| netflix在线观看网站| 亚洲七黄色美女视频| 动漫黄色视频在线观看| 日本vs欧美在线观看视频| 久久精品国产亚洲av香蕉五月| 看免费av毛片| 国产成人精品久久二区二区91| 日韩中文字幕欧美一区二区| 精品一区二区三区四区五区乱码| 久久婷婷人人爽人人干人人爱 | 亚洲av熟女| 亚洲国产高清在线一区二区三 | 成熟少妇高潮喷水视频| 午夜福利欧美成人| 热99re8久久精品国产| 色尼玛亚洲综合影院| 亚洲国产毛片av蜜桃av| 亚洲欧美激情综合另类| 丁香欧美五月| 成熟少妇高潮喷水视频| 国产精品久久久久久精品电影 | www.精华液| 国产成人系列免费观看| 女警被强在线播放| 亚洲中文字幕一区二区三区有码在线看 | 91成人精品电影| 首页视频小说图片口味搜索| av中文乱码字幕在线| 99久久精品国产亚洲精品| 天天躁夜夜躁狠狠躁躁| 久久这里只有精品19| 久久人人精品亚洲av| x7x7x7水蜜桃| 午夜视频精品福利| 狠狠狠狠99中文字幕| 国产精品乱码一区二三区的特点 | 九色国产91popny在线| 1024香蕉在线观看| 亚洲欧洲精品一区二区精品久久久| 男女午夜视频在线观看| 免费在线观看黄色视频的| 国产欧美日韩一区二区三区在线| 可以在线观看的亚洲视频| 村上凉子中文字幕在线| 老司机福利观看| 免费少妇av软件| 亚洲人成伊人成综合网2020| 18禁观看日本| 很黄的视频免费| 色在线成人网| 精品午夜福利视频在线观看一区| 国产真人三级小视频在线观看| 免费久久久久久久精品成人欧美视频| 黄色女人牲交| 国产成人av激情在线播放| 99精品欧美一区二区三区四区| 久久人人爽av亚洲精品天堂| 国产精品免费一区二区三区在线| 高清在线国产一区| 亚洲熟妇熟女久久| 两性午夜刺激爽爽歪歪视频在线观看 | 丁香六月欧美| 极品教师在线免费播放| 欧美精品啪啪一区二区三区| 电影成人av| 精品国产超薄肉色丝袜足j| 欧美日韩福利视频一区二区| 国产男靠女视频免费网站| 久久草成人影院| 丰满的人妻完整版| 免费观看精品视频网站| 嫩草影院精品99| 免费在线观看视频国产中文字幕亚洲| 午夜亚洲福利在线播放| 亚洲专区国产一区二区| 亚洲人成电影观看| 12—13女人毛片做爰片一| e午夜精品久久久久久久| 美女免费视频网站| 色尼玛亚洲综合影院| 一二三四社区在线视频社区8| 成人精品一区二区免费| av视频在线观看入口| 国产亚洲精品久久久久久毛片| 国产欧美日韩综合在线一区二区| 韩国精品一区二区三区| 欧美黄色淫秽网站| avwww免费| 亚洲精品国产色婷婷电影| 亚洲av成人av| 欧美乱色亚洲激情| 丝袜人妻中文字幕| 日韩免费av在线播放| 操美女的视频在线观看| 巨乳人妻的诱惑在线观看| 午夜久久久在线观看| 亚洲,欧美精品.| 在线国产一区二区在线| 日本a在线网址| 一边摸一边做爽爽视频免费| 一进一出抽搐动态| 无遮挡黄片免费观看| 老司机福利观看| 亚洲男人天堂网一区| 中文字幕av电影在线播放| 精品国产乱码久久久久久男人| 变态另类成人亚洲欧美熟女 | 成人av一区二区三区在线看| 99久久精品国产亚洲精品| 午夜a级毛片| 亚洲精品av麻豆狂野| 精品国产乱码久久久久久男人| 久久国产精品影院| 国产熟女午夜一区二区三区| 婷婷精品国产亚洲av在线| 日本三级黄在线观看| 美女高潮喷水抽搐中文字幕| 午夜日韩欧美国产| 亚洲国产欧美一区二区综合| 在线观看www视频免费|